Cytiva’s 2025 Global Biopharma Index highlights declining ecosystem resilience with an average score dip to 5.96 from 6.08 in 2023. The report notes improved supply chain robustness but continuing talent shortages and regulatory uncertainty, particularly impacting the U.S., which fell to fifth place. South Korea’s leap to third reflects strategic investments in digital innovation and clinical capacity. Industry leaders emphasize increasing regionalism and the need for collaborative strategies to sustain innovation amid geopolitical volatility.